Emerging research suggest Retatrutide , a dual agonist targeting both incretin and GIP , may offer a promising step forward for body management . Early human investigations have demonstrated impressive decreases in visceral tissue, potentially exceeding other obesity therapies . However , additional study is required to completely assess its lastin